Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Vlad Ratziu, Stephen A. Harrison, Sven Francque, +65

Gastroenterology

ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

Péter Ferenci, David Bernstein, Jacob Lalezari, +26

New England Journal of Medicine

Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1

Thomas Boyer, Arun J. Sanyal, Florence Wong, +63

Gastroenterology

HepatologyLiver PhysiologyPharmacologyAcute Liver FailureTerlipressin Plus Albumin +5

Perforation During Colonoscopy in Endoscopic Ambulatory Surgical Centers

Louis Y. Korman, Bergein F. Overholt, Terry Box, +1

Gastrointestinal Endoscopy

GastroenterologySurgeryColonoscopyInterventional EndoscopyMedicine

Mathematical modeling of liver injury and dysfunction after acetaminophen overdose: Early discrimination between survival and death

Christopher H. Remien, Frederick R. Adler, Lindsey Waddoups, +2

Hepatology

Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: The national experience#*

Jason J. Schwartz, Lisa M. Pappas, Heather F. Thiesset, +6

Liver Transplantation

Expanding primary care capacity to treat hepatitis C virus infection through an evidence-based care model--Arizona and Utah, 2012-2014.

Kiren Mitruka, Karla Thornton, Susanne M. Cusick, +7

UNM’s Digital Repository (University of New Mexico)

Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection

Eric Lawitz, William O’Riordan, Armen Asatryan, +10

Antimicrobial Agents and Chemotherapy

Hcv Ns5a InhibitorImmunologyPharmacotherapyAntiviral DrugAutoimmune Liver Disease +16

1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12

Stefan Zeuzem, S. Arora, B. Bacon, +45

Journal of Hepatology

Viral PersistenceViral HepatitisImmunodeficienciesImmunologyAntiviral Therapy +8

Racial Differences in Response Rates to Consensus Interferon in HCV Infected Patients Naive to Previous Therapy

Paul J. Gaglio, M. Rodríguez‐Torres, Robert Herring, +4

Journal of Clinical Gastroenterology